1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Target Diseases and Rising Reimbursements for the Treatment
4.2.2 Research and Development for Effective Treatment
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value – USD)
5.1 By Treatment Types
5.1.1 Medication
5.1.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.1.1.2 TNF Inhibitors
5.1.1.3 IL-17 Inhibitors
5.1.1.4 Others
5.1.2 Therapy
5.1.3 Surgery
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG (Sandoz)
6.1.2 AbbVie Inc.
6.1.3 UCB
6.1.4 Amgen Inc.
6.1.5 Boehringer Ingelheim International GmbH
6.1.6 Celltrion Healthcare
6.1.7 Reliance Life Sciences
6.1.8 Johnson & Johnson Services, Inc.
6.1.9 Eli Lilly and Company
6.1.10 Gilead Sciences, Inc.
6.1.11 Merck & Co., Inc.
6.1.12 Pfizer Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS